Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.
History
It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[4]
Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.[4]